CASI Pharmaceuticals annual return on equity
2021
2022
2023
2024
CASI Pharmaceuticals Return on Equity (ROE) Growth & History (CASIF)
CASI Pharmaceuticals's return on equity was −301.80% for fiscal 2024.
View full CASI Pharmaceuticals company overviewCASI Pharmaceuticals annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −301.80% | −223.36 pp |
| 2023 | 2023-12-31 | −78.44% | −14.89 pp |
| 2022 | 2022-12-31 | −63.55% | −19.40 pp |
| 2021 | 2021-12-31 | −44.15% | — |
CASI Pharmaceuticals quarterly return on equity
Q4.24
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q4 2024 | 2024-12-31 | −110.47% | — |
CASI Pharmaceuticals return on equity trends
Between the periods ended 2021-12-31 and 2024-12-31, CASI Pharmaceuticals's return on equity decreased from −44.15% to −301.80%, a change of −257.65 percentage points. The latest reported quarter, Q4 2024, shows −110.47%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CASI Pharmaceuticals source filings ↗